Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan;73(1):17–48.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9–32. doi: 10.20892/j.issn.2095-3941.2016.0084
   PubMed Web of Science ®Google Scholar
• Rojas V, Hirshfield KM, Ganesan S, et al. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. Int J Mol Sci. 2016 Dec 15;17(12):2113. doi: 10.3390/ijms17122113
   PubMed Web of Science ®Google Scholar
• Kossai M, Leary A, Scoazec JY, et al. Ovarian Cancer: A Heterogeneous Disease. Pathobiology. 2018;85(1–2):41–49. doi: 10.1159/000479006
   PubMed Web of Science ®Google Scholar
• Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009 Sep;16(5):267–82. doi: 10.1097/PAP.0b013e3181b4fffa
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019 Jul;69(4):280–304. doi: 10.3322/caac.21559
   PubMed Web of Science ®Google Scholar
• Kaldawy A, Segev Y, Lavie O, et al. Low-grade serous ovarian cancer: A review. Gynecol Oncol. 2016 Nov;143(2):433–438.
   PubMed Web of Science ®Google Scholar
• Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020 Mar;156(3):715–725.
   PubMed Web of Science ®Google Scholar
• Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007 Aug;31(8):1168–74.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER explorer: an interactive website for SEER cancer statistics 2023 [cited 2023 Jun 26] Available from: https://seer.cancer.gov/statistics-network/explorer/
   Google Scholar
• Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet. 2023 Jun 20;34(5). doi: 10.3802/jgo.2023.34.e85
   Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471–4. doi: 10.1245/s10434-010-0985-4
   PubMed Web of Science ®Google Scholar
• Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9;371:m3773. doi: 10.1136/bmj.m3773
   PubMedGoogle Scholar
• Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical Oncology clinical Practice Guideline. Gynecol Oncol. 2016 Oct;143(1):3–15.
   PubMed Web of Science ®Google Scholar
• Garzon S, Lagana AS, Casarin J, et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland Surg. 2020 Aug;9(4):1118–1129.
   PubMed Web of Science ®Google Scholar
• Glajzer J, Grabowski JP, Sehouli J, et al. Recurrent treatment in ovarian cancer patients: what are the best regimens and the order they should be given? Curr Treat Options Oncol. 2020 Apr 30;21(6):49. doi: 10.1007/s11864-020-00747-7
   PubMed Web of Science ®Google Scholar
• Chandra A, Pius C, Nabeel M, et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019 Nov;8(16):7018–7031. doi: 10.1002/cam4.2560
   PubMed Web of Science ®Google Scholar
• Haunschild CE, Tewari KS. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 2020 Mar;16(7):225–246. doi: 10.2217/fon-2019-0042
   PubMed Web of Science ®Google Scholar
• Coleman RL, Spirtos NM, Enserro D, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019 Nov 14;381(20):1929–1939. doi: 10.1056/NEJMoa1902626
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, et al. Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17(Suppl 5):v7–12.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Gaya A. Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer. Cancer Treat Rev. 2002 Apr;28(2):121–5. doi: 10.1053/ctrv.2002.0262
   PubMed Web of Science ®Google Scholar
• Nicoletto RE, Ofner CM. 3rd. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol. 2022 Mar;89(3):285–311. doi: 10.1007/s00280-022-04400-y
   PubMed Web of Science ®Google Scholar
• Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020 Dec;31(12):1606–1622.
   PubMed Web of Science ®Google Scholar
• Frenel JS, Kim JW, Aryal N, et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT ov-21 trial. Ann Oncol. 2022 Oct;33(10):1021–1028.
   PubMed Web of Science ®Google Scholar
• Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022 Feb;164(2):254–264.
   PubMed Web of Science ®Google Scholar
• O’Cearbhaill RE, Perez-Fidalgo JA, Monk BJ, et al. Efficacy of niraparib by time of surgery and postoperative residual disease status: a post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022 Jul;166(1):36–43.
   PubMed Web of Science ®Google Scholar
• Li H, Liu ZY, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0
   PubMed Web of Science ®Google Scholar
• Klotz DM, Wimberger P. Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies? Arch Gynecol Obstet. 2020 Nov;302(5):1087–1102. doi: 10.1007/s00404-020-05677-1
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• FDA-NIH Biomarker Working Group. Diagnostic Biomarker. Silver Spring (MD): Food and Drug Adminstration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Monitoring biomarker. Silver Spring (MD): Food and Drug Adminstration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Response biomarker. Silver Spring MD: Food and Drug Adminstration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Predictive biomarker. Silver Spring MD: Food and Drug Administration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Prognostic biomarker. Silver Spring MD: Food and Drug Administration (US); 2016. BEST (Biomarkers, EndpointS and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Safety biomarker. Silver Spring MD: Food and Drug Administration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. Susceptibility/Risk biomarker. Silver Spring MD: Food and Drug Administration (US); 2016. BEST (Biomarkers, EndpointS, and other Tools) Resource.
   Google Scholar
• FDA-NIH Biomarker Working Group. BEST (biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD). Bethesda (MD): National Institutes of Health (US); 2016.
   Google Scholar
• Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018 Feb;243(3):213–221. doi: 10.1177/1535370217750088
   PubMed Web of Science ®Google Scholar
• Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl. 2008 Oct 1;2(10–11):1386–1402. doi: 10.1002/prca.200780174
   PubMed Web of Science ®Google Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation–quality assurance and control of protein biomarker assays. Mol Oncol. 2014 Jun;8(4):840–58. doi: 10.1016/j.molonc.2014.03.006
   PubMed Web of Science ®Google Scholar
• U.S. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. 21st century cures : examining the regulation of laboratory-developed tests : hearing before the Subcommittee on health of the Committee on Energy and Commerce, House of Representatives, one hundred thirteenth Congress, second session. (WA) DC: U.S. Government Publishing Office. Sep 9, 2014. For sale by the Superintendent of Documents; 2016.
   Google Scholar
• Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med. 2012 Aug 9;10:87. doi: 10.1186/1741-7015-10-87
   PubMed Web of Science ®Google Scholar
• Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 3;106(5). doi: 10.1093/jnci/dju048
   Google Scholar
• Hawarden A, Price, M, Russell, B, et al. A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer. Plos One. 2023;18(3):e0281798. doi: 10.1371/journal.pone.0281798
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HS, Suh DH, et al. Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev. 2013 Dec;18(4):298–312.
   PubMedGoogle Scholar
• Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with Triple-Negative breast cancer. Clin Cancer Res. 2016 Aug 1;22(15):3764–73. doi: 10.1158/1078-0432.CCR-15-2477
   PubMed Web of Science ®Google Scholar
• Saorin A, Di Gregorio E, Miolo G, et al. Emerging role of metabolomics in ovarian cancer diagnosis. Metabolites. 2020 Oct 19;10(10). doi: 10.3390/metabo10100419
   PubMed Web of Science ®Google Scholar
• Chaudhry S, Thomas SN, Simmons GE Jr. Targeting lipid metabolism in the treatment of ovarian cancer. Oncotarget. 2022;13:768–783. doi: 10.18632/oncotarget.28241
   PubMedGoogle Scholar
• Bast RC Jr., Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–7.
   PubMed Web of Science ®Google Scholar
• Ueland FR. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics. 2017 Mar 8;7(1). doi: 10.3390/diagnostics7010014
   Web of Science ®Google Scholar
• Zhang H, Liu T, Zhang Z, et al. Integrated Proteogenomic Characterization of human high-grade serous ovarian cancer. Cell. 2016 Jul 28;166(3):755–765. doi: 10.1016/j.cell.2016.05.069
   PubMed Web of Science ®Google Scholar
• Bonifacio VDB. Ovarian cancer biomarkers: moving forward in early detection. Adv Exp Med Biol. 2020;1219:355–363.
   PubMed Web of Science ®Google Scholar
• Zhang R, Siu MKY, Ngan HYS, et al. Molecular biomarkers for the early detection of ovarian cancer. Int J Mol Sci. 2022 Oct 10;23(19):12041. doi: 10.3390/ijms231912041
   PubMed Web of Science ®Google Scholar
• Funston G, Mounce LT, Price S, et al. CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records. Br J Gen Pract. 2021 Jun;71(707):e465–e472.
   PubMed Web of Science ®Google Scholar
• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011 Jun 8;305(22):2295–303. doi: 10.1001/jama.2011.766
   PubMed Web of Science ®Google Scholar
• Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009 Sep;9(6):555–66.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):2995–9. doi: 10.1158/1055-9965.EPI-10-0580
   PubMed Web of Science ®Google Scholar
• Dochez V, Caillon H, Vaucel E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019 Mar 27;12(1):28. doi: 10.1186/s13048-019-0503-7
   PubMedGoogle Scholar
• Coleman RL, Herzog TJ, Chan DW, et al. Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses. Am J Obstet Gynecol. 2016 Jul;215(1):82 e1–82 e11.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Backes FJ, et al. NCCN Guidelines(R) insights: ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 2022 Sep;20(9):972–980.
   PubMedGoogle Scholar
• Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. Plos One. 2014;9(4):e95192. doi: 10.1371/journal.pone.0095192
   PubMed Web of Science ®Google Scholar
• Deutsch EW, Omenn GS, Sun Z, et al. Advances and utility of the human plasma proteome. J Proteome Res. 2021 Dec 3;20(12):5241–5263. doi: 10.1021/acs.jproteome.1c00657
   PubMed Web of Science ®Google Scholar
• Olink. Home - Olink. 2023 [cited 2023 Jul 10-24]. Available from: https://olink.com/
   Google Scholar
• Olink. Olink Explore 3072 Validation Data Results. 2023 [cited 2023 Jul 22-24]. Available from: https://olink.com/resources-support/document-download-center/#:~:text=Validation%20data%20results
   Google Scholar
• Olink. Olink Explore 3072 Validation Method & Results. 2023 [cited 2023 Jul 22-24]. Available from: https://olink.com/content/uploads/2022/10/olink-explore-validation-data.pdf
   Google Scholar
• Olink. Explore HT - Olink. 2023 [cited 2023 Jul 24]. Available from: https://olink.com/products-services/exploreht/
   Google Scholar
• Kobayashi H, Looker HC, Satake E, et al. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney Int. 2022 Aug;102(2):370–381.
   PubMed Web of Science ®Google Scholar
• Candia J, Daya GN, Tanaka T, et al. Assessment of variability in the plasma 7k SomaScan proteomics assay. Sci Rep. 2022 Oct 13;12(1):17147. doi: 10.1038/s41598-022-22116-0
   PubMed Web of Science ®Google Scholar
• Davies MPA, Sato T, Ashoor H, et al. Plasma protein biomarkers for early prediction of lung cancer. EBioMedicine. 2023 Jun 26;93:104686. doi: 10.1016/j.ebiom.2023.104686
   PubMed Web of Science ®Google Scholar
• Luo Y, Wadhawan S, Greenfield A, et al. Somascan proteomics identifies serum biomarkers associated with liver fibrosis in patients with NASH. Hepatol Commun. 2021 May;5(5):760–773.
   PubMed Web of Science ®Google Scholar
• Dammer EB, Ping L, Duong DM, et al. Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther. 2022 Nov 17;14(1):174. doi: 10.1186/s13195-022-01113-5
   PubMed Web of Science ®Google Scholar
• Graumann J, Finkernagel F, Reinartz S, et al. Multi-platform affinity proteomics identify proteins linked to metastasis and Immune Suppression in ovarian cancer plasma. Front Oncol. 2019;9:1150. doi: 10.3389/fonc.2019.01150
   PubMed Web of Science ®Google Scholar
• Finkernagel F, Reinartz S, Schuldner M, et al. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment. Theranostics. 2019;9(22):6601–6617. doi: 10.7150/thno.37549
   PubMed Web of Science ®Google Scholar
• Van Eeckhaut A, Lanckmans K, Sarre S, et al. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Aug 1;877(23):2198–207. doi: 10.1016/j.jchromb.2009.01.003
   PubMed Web of Science ®Google Scholar
• Kristiansen J. Description of a generally applicable model for the evaluation of uncertainty of measurement in clinical chemistry. Clin Chem Lab Med. 2001 Oct;39(10):920–31. doi: 10.1515/CCLM.2001.148
   PubMed Web of Science ®Google Scholar
• Rudzki PJ, Gniazdowska E, Bus-Kwasnik K. Quantitative evaluation of the matrix effect in bioanalytical methods based on LC-MS: a comparison of two approaches. J Pharm Biomed Anal. 2018 Jun 5;155:314–319. doi: 10.1016/j.jpba.2018.03.052
   PubMed Web of Science ®Google Scholar
• Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003 Jul 1;75(13):3019–30. doi: 10.1021/ac020361s
   PubMed Web of Science ®Google Scholar
• Sun J, Wang Z, Yang C. Ion mobility mass spectrometry development and applications. Crit Rev Anal Chem. 2022 Nov;3:1–8. doi: 10.1080/10408347.2022.2139589
   Google Scholar
• Aslam B, Basit M, Nisar MA, et al. Proteomics: technologies and their applications. J Chromatogr Sci. 2017 Feb;55(2):182–196.
   PubMed Web of Science ®Google Scholar
• Rozanova S, Barkovits K, Nikolov M, et al. Quantitative mass spectrometry-based proteomics: an overview. Methods Mol Biol. 2021;2228:85–116.
   PubMedGoogle Scholar
• Keener JE, Zhang G, Marty MT. Native mass spectrometry of membrane proteins. Anal Chem. 2021 Jan 12;93(1):583–597. doi: 10.1021/acs.analchem.0c04342
   PubMed Web of Science ®Google Scholar
• Li J, Zhan X. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas. Biochim Biophys Acta Proteins Proteom. 2021 Mar;1869(3):140584. doi: 10.1016/j.bbapap.2020.140584
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Schirle M, Sweetman G, et al. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem. 2007 Oct;389(4):1017–31.
   PubMed Web of Science ®Google Scholar
• Pernemalm M, Lehtio J. Mass spectrometry-based plasma proteomics: state of the art and future outlook. Expert Rev Proteomics. 2014 Aug;11(4):431–48. doi: 10.1586/14789450.2014.901157
   PubMed Web of Science ®Google Scholar
• Coombes KR. Analysis of mass spectrometry profiles of the serum proteome. Clin Chem. 2005 Jan;51(1):1–2. doi: 10.1373/clinchem.2004.040832
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Mischak H. Mass spectrometry based proteomics in urine biomarker discovery. World J Urol. 2007 Oct;25(5):435–43. doi: 10.1007/s00345-007-0206-3
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhang F, Xu L, et al. High-throughput proteomics and AI for cancer biomarker discovery. Adv Drug Deliv Rev. 2021 Sep;176:113844. doi: 10.1016/j.addr.2021.113844
   PubMed Web of Science ®Google Scholar
• Schuster-Little N, Fritz-Klaus R, Etzel M, et al. Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites. Analyst. 2021 Jan 4;146(1):85–94. doi: 10.1039/D0AN01701A
   PubMed Web of Science ®Google Scholar
• Dodds JN, Baker ES. Ion mobility spectrometry: fundamental concepts, instrumentation, applications, and the road ahead. J Am Soc Mass Spectrom. 2019 Nov;30(11):2185–2195. doi: 10.1007/s13361-019-02288-2
   PubMed Web of Science ®Google Scholar
• Tao L, McLean JR, McLean JA, et al. A collision cross-section database of singly-charged peptide ions. J Am Soc Mass Spectrom. 2007 Jul;18(7):1232–8.
   PubMed Web of Science ®Google Scholar
• Cohen MJ, Karasek FW. Plasma chromatography - a New dimension for gas chromatography and mass spectrometry. J Chromatogr Sci. 1970;8(6):330–&. doi: 10.1093/chromsci/8.6.330
   Web of Science ®Google Scholar
• Wu C, Siems WF, Asbury GR, et al. Electrospray ionization high-resolution ion mobility spectrometry-mass spectrometry. Anal Chem. 1998 Dec 1;70(23):4929–38. doi: 10.1021/ac980414z
   PubMed Web of Science ®Google Scholar
• Shvartsburg AA, Smith RD. Fundamentals of traveling wave ion mobility spectrometry. Anal Chem. 2008 Dec 15;80(24):9689–99. doi: 10.1021/ac8016295
   PubMed Web of Science ®Google Scholar
• Meier F, Park MA, Mann M. Trapped ion mobility spectrometry and parallel accumulation-serial fragmentation in proteomics. Mol & Cell Proteomics. 2021;20:100138. doi: 10.1016/j.mcpro.2021.100138
   PubMed Web of Science ®Google Scholar
• Abdulbagi M, Wang L, Siddig O, et al. D-Amino acids and D-Amino acid-containing peptides: potential disease biomarkers and therapeutic targets? Biomolecules. 2021 Nov 18;11(11). doi: 10.3390/biom11111716
   PubMed Web of Science ®Google Scholar
• Du S, Wang Y, Alatrash N, et al. Altered profiles and metabolism of l- and d-amino acids in cultured human breast cancer cells vs. non-tumorigenic human breast epithelial cells. J Pharm Biomed Anal. 2019 Feb 5;164:421–429. doi: 10.1016/j.jpba.2018.10.047
   PubMed Web of Science ®Google Scholar
• Charkow J, Rost HL. Trapped ion mobility spectrometry reduces spectral complexity in mass spectrometry-based proteomics. Anal Chem. 2021 Dec 21;93(50):16751–16758. doi: 10.1021/acs.analchem.1c01399
   PubMed Web of Science ®Google Scholar
• Valentine S, Kulchania M, Srebalus Barnes C, et al. Multidimensional separations of complex peptide mixtures: a combined high-performance liquid chromatography/ion mobility/time-of-flight mass spectrometry approach. Int J Mass Spectrom. 2001;212(1–3):97–109. doi: 10.1016/S1387-3806(01)00511-5
   Web of Science ®Google Scholar
• Valentine SJ, Plasencia MD, Liu X, et al. Toward plasma proteome profiling with ion mobility-mass spectrometry. J Proteome Res. 2006 Nov;5(11):2977–84.
   PubMed Web of Science ®Google Scholar
• Li C, Chu S, Tan S, et al. Towards higher sensitivity of mass spectrometry: a perspective from the mass analyzers. Front Chem. 2021;9:813359. doi: 10.3389/fchem.2021.813359
   PubMed Web of Science ®Google Scholar
• Crowell KL, Baker ES, Payne SH, et al. Increasing confidence of LC-MS identifications by utilizing ion mobility spectrometry. Int J Mass Spectrom. 2013 Nov 15;354-355:312–317. doi: 10.1016/j.ijms.2013.06.028
   PubMed Web of Science ®Google Scholar
• Song G, Chen L, Zhang B, et al. Proteome-wide Tyrosine Phosphorylation analysis Reveals Dysregulated Signaling Pathways in ovarian tumors. Mol & Cell Proteomics. 2019 Mar;18(3):448–460.
   PubMed Web of Science ®Google Scholar
• Abbott KL, Lim JM, Wells L, et al. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics. 2010 Feb;10(3):470–81.
   PubMed Web of Science ®Google Scholar
• Lienard R, Duez Q, Grayson SM, et al. Limitations of ion mobility spectrometry-mass spectrometry for the relative quantification of architectural isomeric polymers: a case study. Rapid Commun Mass Spectrom. 2020 Aug;34(Suppl 2):e8660.
   PubMedGoogle Scholar
• Kirk AT, Bohnhorst A, Raddatz CR, et al. Ultra-high-resolution ion mobility spectrometry-current instrumentation, limitations, and future developments. Anal Bioanal Chem. 2019 Sep;411(24):6229–6246.
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Kiyotani K, Nemoto K, et al. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations. Commun Biol. 2022 Aug 18;5(1):831. doi: 10.1038/s42003-022-03807-w
   PubMed Web of Science ®Google Scholar
• Sutinen M, Kontunen A, Karjalainen M, et al. Identification of breast tumors from diathermy smoke by differential ion mobility spectrometry. Eur J Surg Oncol. 2019 Feb;45(2):141–146.
   PubMed Web of Science ®Google Scholar
• Haapala I, Karjalainen M, Kontunen A, et al. Identifying brain tumors by differential mobility spectrometry analysis of diathermy smoke. J Neurosurg. 2019 Jun;14:1–7.
   Google Scholar